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Introduction
Vitamin D (calciferol) includes a group of liposoluble
secosteroids that are essential in the homeostasis of
calcium and phosphate through the regulation of
hundreds of genes in animal metabolism.[1] Vitamin D
deficiency is a great concern for human health be-
cause it causes rickets in children and osteomalacia
in adults. An inadequate amount of vitamin D can in-
crease the risk of bone fractures in elderly people
and, more recently, it has been associated to an in-
creased risk of cancers, cardiovascular diseases, im-
munodeficiency, and diabetes.[1, 2] Cholecalciferol (vi-
tamin D3, Figure 1A) and ergocalciferol (vitamin D2;
Figure 1B) can be obtained through dietary intake.
Vitamin D3, derived from cholesterol metabolism in
animals, is naturally present in foods, such as fish,
meat, eggs, and milk, whereas vitamin D2 is present in com-
mercially irradiated mushrooms and yeast,[3] where it is formed
from fungal ergosterol.[4] Additionally, vitamin D3 is produced
in human skin and converted to active hydroxylated metabo-
lites in the liver and kidneys, as described in Figure 2. 25-Hy-
droxyvitamin D3 (25-hydroxycholecalciferol) is the first metabol-
ically active, and the major form, of circulating vitamin D (used
to detect vitamin deficiency), whereas 1a,25-dihydroxyvita-
min D3 (calcitriol) is the major active form. Vitamin D2 obtained
from our diet undergoes an analogous set of activation steps
to give 25-hydroxyergocalciferol and 1a,25-dihydroxyergocalci-
ferol.
It has been shown that for diseases, such as hyperglycemia,
chronic kidney disease, and for anephric patients, supplemen-
tation with 25-hydroxycholecalciferol has a positive effect[5–7]
owing to, in some cases, the extrarenal hydroxylation of this
metabolite.[6] Similar findings have also been reported for
Crohn’s disease and intestinal resection, as well as for chronic
cholestatic liver disease.[8,9] In addition to the physiological in-
terest in 25-hydroxycholecalciferol for human health, this com-
pound has also raised interest for the feeding of poultry[10–13]
and other farm animals.[14] The poor-quality skeletons of broiler
chickens is currently a serious problem that has a negative in-
fluence on the economic benefits of rearing these birds. The
Monohydroxylated metabolites of vitamin D3 (cholecalciferol)
and vitamin D2 (ergocalciferol), generically known as 25-hy-
droxycalciferol, are better for several diseases, and other appli-
cations, than vitamin D (calciferol). This work describes a novel
biotechnological approach for the preparation of 25-hydroxy-
calciferols, starting from readily available cholecalciferol and er-
gocalciferol. This approach enables the regioselective (100%)
hydroxylation of these compounds (at the C-25 position)
under mild and environmentally friendly conditions by using
a peroxidase from the fungus Coprinopsis cinerea (gene model
CC1G_08427T0 from the sequenced genome), which catalyzes
monooxygenation with H2O2 as the only co-substrate (peroxy-
genase). Hydroxylation of cholecalciferol and ergocalciferol is
a true peroxygenation, as demonstrated by incorporation of
18O from H2
18O2 into the products. The peroxygenase has addi-
tional advantages related to its recombinant nature, enabling
enzyme engineering and low-cost overexpression in an indus-
trial host. Therefore, the peroxygenase is a promising biocata-
lyst for the production of vitamin D active metabolites.
Figure 1. Chemical structures of the two vitamin D forms, cholecalciferol (vitamin D3, A)
and ergocalciferol (vitamin D2, B), tested as substrates for the recombinant peroxyge-
nase.
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addition of 25-hydroxycholecalciferol into feed mixtures has
been shown to have a favorable effect.[10] Therefore, both vita-
min D3, D2, and their hydroxylated derivatives are approved
food additives.[15]
In addition to the biosynthesis of naturally hydroxylated vita-
min D3 by animals, and production of hydroxylated vitamin D2
from fungal ergosterol by UV irradiation, chemical synthesis
(total or partial) for the production of these active compounds
has attracted much interest, and several approaches have
been reported.[11,16–22] As a sustainable alternative, biotechno-
logical approaches have been investigated, including microbial
oxygenations in the production of vitamin D derivatives.[23, 24]
Moreover, enzymes (monooxygenases containing both heme
and flavin cofactors) are capable of catalyzing the selective
oxyfunctionalization of organic
substrates under mild and envi-
ronmentally friendly condi-
tions.[25] Members of the cyto-
chrome P450 monooxygenase
(P450) superfamily are remark-
able examples of such cata-
lysts.[26–29] However, large-scale
applications are limited because
of the intrinsic properties of
P450s.[30]
Recently, a new type of perox-
idase was discovered in the basi-
diomycete Agrocybe aegerita[31]
that turned out to be a true per-
oxygenase efficiently transferring
oxygen from peroxide to various
organic substrates.[32–34] Only
a few similar enzymes have been
characterized from related fungi,
but there are indications of their
widespread occurrence.[35–37] For
example, over 100 related genes,
classified in the new superfamily
of heme–thiolate peroxidas-
es,[33,38] have recently been iden-
tified in the screening of 24 se-
quenced genomes of basidiomy-
cetes,[39] including Coprinopsis
cinerea. To date, wild peroxyge-
nase has not been isolated from
C. cinerea cultures, but the corre-
sponding genes from the
genome were heterologously ex-
pressed by Novozymes A/S
(Bagsvaerd, Denmark).[40] The
monooxygenation ability of one
of these recombinant enzymes
(protein ID 7249 from the C. cin-
erea genome available at the
JGI; http://genome.jgi.doe.gov/
Copci1) has recently been ex-
ploited for the hydroxylation of
fatty acids, fatty alcohols, and long-chain alkanes.[41] Herein,
the ability and efficiency of the recombinant C. cinerea peroxy-
genase in the hydroxylation of vitamin D3 and D2, is evaluated
for the first time.
Results
The current work proposes a biotechnological approach to
obtain both 25-hydroxycholecalciferol and 25-hydroxyergocal-
ciferol starting from readily available and low-cost cholecalci-
ferol and ergocalciferol, respectively, by using an enzyme from
C. cinerea, which is representative of the new fungal peroxi-
dases with monooxygenase activity (peroxygenases) first de-
scribed in A. aegerita. With this purpose, the reaction of the
Figure 2. Human metabolism of vitamin D3 showing the key metabolites. On exposure to UV light in the skin, pro-
vitamin D3 (7-dehydrocholesterol) is converted to previtamin D3, which is isomerized to more stable vitamin D3
(cholecalciferol) via a thermally induced transformation. Vitamin D3, either cutaneously formed or taken in the
diet, is then hydroxylated in the liver to 25-hydroxyvitamin D3 (25-hydroxycholecalciferol). Finally, 25-hydroxyvita-
min D3 is hydroxylated again, primarily in the kidney, to give 1a,25-dihydroxyvitamin D3 (calcitriol), the major bio-
logically active form of vitamin D.
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latter secosterols with the recombinant peroxygenase was
studied, and the substrate conversion rate and product iden-
tification were carried out by GC-MS.
Enzymatic hydroxylation of cholecalciferol at the C-25 posi-
tion
Firstly, cholecalciferol (Figure 1A) was tested as a peroxygenase
substrate. The GC-MS analysis of the reaction revealed that this
compound was completely transformed by the C. cinerea
enzyme within 60 min (Figure 3A). The control reaction with-
out peroxygenase is shown in Figure 3B. The conversion
showed strict regioselectivity and provided 25-hydroxychole-
calciferol exclusively (100% yield), as confirmed by comparison
to a true standard of this compound (Figure 3C), which
showed an identical retention time.
The double peaks observed in the chromatograms for each
substrate and product (Figure 3) correspond to the isopyro
(19b, 9b) and pyro (19a, 9a) isomers formed by thermal rear-
rangement involving ring-B closure, which vitamin D and its
hydroxylated derivatives undergo because of the temperature
at which GC-MS EI(+) analysis is carried out. Indeed, the pres-
ence of the two isomers during GC separation is a useful indi-
cation that a secosteroid of the vitamin D-type was injected
into the system.[42] Therefore, both the chromatographic pro-
files (Figure 3) and the mass spectra discussed below (Figure 4)
correspond to the isomerized secosteroids.
The position of the hydroxyl group at C-25 was established
by mass spectrometry of the trimethylsilyl (TMS) derivative.
The spectrum in Figure 4A shows a prominent ion from C-24/
C-25 bond cleavage, with a characteristic fragment at m/z 131
and a molecular ion at m/z 544. Additionally, characteristic
fragments at m/z 529 ([M15]+), m/z 454 ([M90]+), m/z 439
([M9015]+), m/z 349 ([M909015]+), and m/z 413, were
also present. The spectrum of standard 25-hydroxycholecalci-
ferol is shown in the inset of Figure 4A, and is identical to that
obtained from the peroxygenase reaction. It should be noted
that the mass spectra in Figure 4 are from vitamin D pyroderi-
vatives in which ring-B is cyclized, even if the secosteroid is il-
lustrated, because GC-MS spectra of non-isomerized vitamin D
have not yet been described.[42] The NMR spectra of the reac-
tion product confirmed the formation of 25-hydroxylated vita-
min D3 (unprotonated C-25 with dC=71.3 ppm, and other sig-
nals listed in the Experimental Section).
An 18O-labeling study, using cholecalciferol as substrate and
H2
18O2 as enzyme co-substrate, was performed to investigate
the origin of the oxygen atom incorporated during oxygena-
tion. The results showed that oxygen originating from 18O-la-
beled peroxide (H2
18O2) was completely incorporated into 25-
hydroxycholecalciferol. Mass spectral analysis of the resulting
monohydroxylated cholecalciferol (Figure 4B) showed that the
characteristic fragments had approximately 90% shifted from
the natural abundance at m/z 544, m/z 529, m/z 454, m/z 439,
m/z 349, m/z 131, and m/z 413 found in the unlabeled perox-
ide reaction to m/z 546, m/z 531, m/z 456, m/z 441, m/z 351,
m/z 133, and m/z 415, respectively (10% of the original frag-
ments remained in the H2
18O2 reactions owing to the 90%
18O
isotopic purity of the labeled peroxide).
Enzymatic hydroxylation of ergocalciferol at the C-25 posi-
tion
Hydroxylation of ergocalciferol (Figure 1B), the artificial form of
vitamin D derived from UV irradiation of ergosterol, was also
Figure 3. GC-MS analysis of the C. cinerea peroxygenase reaction (at 60 min)
with cholecalciferol (see Figure 1A) A) showing product formation, B) control
without enzyme, and C) 25-hydroxycholecalciferol standard, as TMS deriva-
tives. In all cases the isopyro (left) and pyro (right) isomers from secosteroid
thermal rearrangement are obtained.
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studied. The peroxygenase from C. cinerea showed similar effi-
ciency, in the transformation of ergocalciferol, to that of chole-
calciferol after 60 min incubation, resulting in 90% substrate
conversion (Figure 5A and B) although the conversion was
slower as found at shorter incubation times (data not shown).
This reaction also showed strict regioselectivity, 25-hydroxyer-
gocalciferol being the only product formed (90% yield), con-
firmed by comparison with a standard (Figure 5C).
The position of the hydroxyl group at C-25 was established
from the mass spectrum (Figure 6), which was identical to that
of a standard (Figure 6, inset). The spectrum shows a prominent
ion from C-24/C-25 bond cleavage, with a characteristic frag-
ment at m/z 131 and a molecular ion at m/z 556. Additionally,
characteristic fragments at m/z 541 ([M15]+), m/z 466
([M90]+), m/z 451
([M9015]+), and m/z 361
([M909015]+), were also
present in the spectrum. In a sim-
ilar manner to the reaction with
cholecalciferol, the peaks of the
two pyroisomers are found in
the chromatogram (Figure 5),
and the mass spectra in Figure 6
are from isomerized vitamin D
derivatives. The NMR spectra of
the reaction product confirmed
the formation of 25-hydroxylated
vitamin D2 (unprotonated C-25
with dC=72.5 ppm, and other
signals listed in the Experimental
Section).
Similar to the cholecalciferol
reaction, 18O-labeling showed
that oxygen originating from
18O-labeled peroxide (H2
18O2)
was completely incorporated
into 25-hydroxyergocalciferol.
Mass spectral analysis (Fig-
ure 6B) showed that the charac-
teristic fragments for the 25-hy-
droxyergocalciferol had approxi-
mately 90% shifted from the
natural abundance at m/z 556,
m/z 541, m/z 466, m/z 451, m/z
361, and m/z 131 found in the
unlabeled peroxide reaction to
m/z 558, m/z 543, m/z 468, m/z
441, m/z 363, and m/z 133, re-
spectively.
Discussion
It has been demonstrated that
the 25-hydroxylated metabolites
of vitamin D, including 25-hy-
droxycholecalciferol and 25-hy-
droxyergocalciferol, are consider-
ably better therapeutic agents for several diseases than vita-
min D itself, owing to their direct biological activity and better
intestinal absorption in some cases.[5,8,9] Likewise, these hy-
droxylated compounds also find applications as animal-feed
supplements (and are superior to vitamin D itself), especially
when their subsequent metabolic conversion is dimin-
ished.[10,43,44] On the other hand, despite some controversy on
which oral formulation of vitamin D (vitamin D3 or D2) is pre-
ferred, and although there are reports that certain animal spe-
cies discriminate against vitamin D2, in humans vitamin D2 and
D3 seem to be essentially equipotent in the prevention and
cure of rickets and possibly other vitamin D actions in the
body.[6] The recognition that both forms of 25-hydroxyvita-
min D exhibit several advantages relative to vitamin D has gen-
Figure 4. Mass spectra of 25-hydroxycholecalciferol from C. cinerea peroxygenase reaction with cholecalciferol in
the presence of A) H2
16O2 (inset is the mass spectrum of standard compound 25-hydroxycholecalciferol) and
B) H2
18O2 (90% isotopic purity), as TMS derivatives.
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erated great interest in the chemical synthesis of these com-
pounds.[11,16–20] However, these reactions often require strong
oxidizing agents, include several steps, are expensive, and
occur with little regioselectivity in the hydroxylation steps.
In contrast to chemical synthesis, the peroxygenase from
the C. cinerea genome is highly selective, and can hydroxylate
the C-25 position of both vitamin D3 and D2 to provide the bio-
logically active hydroxylated forms by means of environmen-
tally friendly and potentially unexpensive reactions. This
enzyme, the sequence of which is also available from GenBank
(XM_001831858), shares 63% of mature protein sequence with
the first described and cloned basidiomycete peroxygenase
from A. aegerita. Similarities include the catalytically relevant
Cys36 (87% identity in the Lys15–Gly66 region around this
heme-iron ligand), Arg189 and Glu196 (involved in reactions
with peroxide), as well as four (Phe76, Phe121, Phe191, and
Phe199) of the five phenylalanine residues at the heme access
cavity of the A. aegerita peroxygenase, and two cysteine resi-
dues (Cys284 and Cys327).[45] These structural similarities justify
the similar oxygenation activities reported in a recent compari-
son of two basidiomycete peroxygenases.[41] However, the
C. cinerea enzyme is superior for vitamin D2/D3 hydroxylation,
resulting in the 90–100% conversion rates reported herein,
whereas 45–77% conversion was obtained with the A. aegerita
and Marasmius rotula peroxygenases under the same reaction
conditions (unpublished).
Selective hydroxylation of vitamin D by the recombinant
C. cinerea peroxygenase, as shown here by MS and NMR analy-
sis, is in agreement with the described subterminal oxygena-
tion of fatty acids, fatty alcohols, and alkanes by this
enzyme,[41] as well as by the A. aegerita peroxygenase.[46,47] It is
worth noting that the structural features of the vitamin D2 side
chain, such as the methyl group at C-24 and the double bond
at C-22, did not preclude the hydroxylation at C-25. In the
above reactions, the basidiomycete enzymes act as true per-
oxygenases, as confirmed by the labeled oxygen of H2
18O2
being incorporated into the formed products. The same was
shown previously, for the peroxygenase-catalyzed oxygenation
of several aliphatic[46] and aromatic compounds,[34] in a series
of reactions that could also be useful for preparing specifically
labeled molecules for diagnostic purposes. The enzymatic reac-
tions described herein could be used for the selective hydrox-
ylation of totally or partially chemically synthesized cholecalci-
ferol (or ergocalciferol) or, more interestingly, could be applied
to natural ergocalciferol obtained by UV irradiation of ergoster-
ol, a sterol characteristic of fungi.[48] The latter UV reaction is
possible because the ergosterol ring-B is doubly unsaturated,
compared with the monounsaturated ring in the main sterols
of plant (sitosterol) and animal (cholesterol) origin (7-dehydro-
cholesterol is a precursor of both cholesterol and vitamin D3).
The chemistry of aliphatic- (and aromatic-) substrate oxygen-
ation by the basidiomycete peroxygenases[49,50] is the same as
that operating in P450s,[27] both enzymes share a heme–thio-
late active center and a FeIV=O compound that transfers the
oxygen atom to the substrate in a two-electron oxidation.
However, unlike P450s, which are intracellular enzymes whose
activation requires NAD(P)H as an electron donor and auxiliary
flavin reductases (or a second flavin domain) for electron trans-
fer to O2 (as shown using
18O2),
[51] the basidiomycete peroxyge-
nases are secreted proteins, therefore, are far more stable, and
only require H2O2 for (direct) activation and subsequent
oxygen transfer to the substrate.[34,52] Owing to the above char-
acteristics, these new basidiomycete enzymes can be consid-
ered as the biocatalysts of choice for enzymatic oxygenations.
Figure 5. GC-MS analysis of the C. cinerea peroxygenase reaction (at 60 min)
with ergocalciferol (see Figure 1B) A) showing product formation, B) control
without enzyme, and C) 25-hydroxyergocalciferol standard, as TMS deriva-
tives. In all cases the isopyro (left) and pyro (right) isomers from secosteroid
thermal rearrangement are obtained.
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The above reasoning is especially true for the vitamin D hy-
droxylation reactions described above because, in addition to
their chemical selectivity, high conversion rates were obtained
resulting in almost complete transformation in a short reaction
time. The efficiency of these peroxygenase reactions is similar
to that recently found for the oxygenation of some alkylben-
zenes and styrene derivatives,[53] but is much higher than that
reported for most peroxygenase reactions, such as fatty acid or
alkane oxygenations, which often result in several products (at
w-1 and w-2 positions) with different oxidation degrees (from
hydroxyl to carbonyl groups).[41, 46,47] Therefore, the production
of biologically active vitamin D forms from both cholecalciferol
and ergocalciferol adds to the list of interesting oxygenation
reactions that basidiomycete peroxygenase can cata-
lyze,[46, 47,54–58] occupying a preeminent position owing to the
high degree of regioselectivity of the enzymatic bioconversion.
Moreover, the recombinant nature of the C. cinerea peroxyge-
nase used, after successful expression in the industrial host As-
pergillus oryzae,[40] permits over expression of the enzyme (as
a low-cost product) and tailoring
of its properties by protein engi-
neering tools, if necessary, to im-
prove industrial applicability.
Conclusions
Fungal peroxygenase, a novel
biocatalyst for environmentally
friendly oxyfunctionalization of
a variety of aromatic and aliphat-
ic compounds, first described in
A. aegerita, is now available for
application in enzymatic reac-
tions after the heterologous ex-
pression of a C. cinerea peroxy-
genase gene in an industrial
host organism. The recombinant
enzyme obtained is evaluated
for the first time in the hydroxyl-
ation of vitamin D, including
both the cholecalciferol and er-
gocalciferol forms. The 100% re-
gioselectivity in the hydroxyl-
ation at the C-25 position, to-
gether with its self-sufficient oxy-
genase activity (i.e. the ability to
catalyze oxygenations without
the help of intracellular enzymes
providing electrons and reduc-
ing power, as in the case of
P450s), and its overexpression in
a suitable host organism, make
this recombinant heme–thiolate
peroxidase an interesting indus-
trial biocatalyst for the synthesis
of 25-hydroxycalciferol.
Experimental Section
Enzyme
The recombinant peroxygenase used in this study corresponds to
gene model CC1G_08427T0 from the sequenced C. cinerea
genome available at the JGI (http://genome.jgi.doe.gov/copci1)
and GenBank (XM_001831858). The corresponding protein (C. ciner-
ea genome ID 7249) was produced by heterologous expression by
using a Novozymes Aspergillus oryzae industrial host system,[40] and
purified by using a combination of S-Sepharose and SP-Sepharose
ion-exchange chromatography. The recombinant peroxygenase
preparation is an electrophoretically homogeneous glycoprotein
with a molecular mass around 44 kDa (a non-uniform glycosylation
pattern was observed), a typical UV/Vis spectrum with a Soret
band at 418 nm, and the ability to oxygenate different aromatic
compounds[59] with a specific activity of approximately 100 Umg1
measured with veratryl alcohol. One enzyme activity unit was de-
fined as the amount of enzyme required to oxidize 1 mmol of ve-
ratryl alcohol to veratraldehyde (e310 9300m
1 cm1) in 1 min at
24 8C, pH 7, in the presence of 0.5 mm H2O2.
Figure 6. Mass spectra of 25-hydroxyergocalciferol from C. cinerea peroxygenase reaction with ergocalciferol in
the presence of A) H2
16O2 (inset is the mass spectrum of standard compound 25-hydroxyergocalciferol) and
B) H2
18O2 (90% isotopic purity), as TMS derivatives.
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Secosteroid substrates and standards
Vitamin D3, also known as calciol or cholecalciferol ((5Z,7E)-(3S)-
9,10-seco-5,7,10(19)-cholestatrien-3-ol), and vitamin D2, also known
as ercalciol or ergocalciferol ((5Z,7E,22E)-(3S)-9,10-seco-
5,7,10(19),22-ergostatetraen-3-ol), were tested as substrates of the
C. cinerea peroxygenase. 25-Hydroxyvitamin D3, also known as cal-
cidiol or 25-hydroxycholecalciferol ((5Z,7E)-(3S)-9,10-seco-5,7,10(19)-
cholestatriene-3,25-diol), and 25-hydroxyvitamin D2, also known as
ercalcidiol or 25-hydroxyergocalciferol ((5Z,7E,22E)-(3S)-9,10-seco-
5,7,10(19),22-ergostatetraene-3,25-diol), were used as standards for
GC-MS analyses. All the compounds were from Sigma–Aldrich.
Enzymatic reactions
Reactions of cholecalciferol and ergocalciferol (0.05 mm) with the
C. cinerea peroxygenase (1 U) were performed in 5 mL of 50 mm
sodium phosphate (pH 7) at 40 8C for 60 min, in the presence of
0.5 mm H2O2. The substrates were previously dissolved in acetone,
and added to the buffer (the acetone concentration in the reaction
was 40%). In the control experiments, the substrates were treated
under the same conditions (including 0.5 mm H2O2), but in the ab-
sence of the enzyme. Enzymatic reactions with 18O-labeled hydro-
gen peroxide [H2
18O2, 90% isotopic content, Sigma–Aldrich (2%
w/v solution)] were also performed under the same conditions as
described above.
After the enzymatic reactions, products were recovered by liquid–
liquid extraction with methyl tert-butyl ether, dried under N2, and
redissolved in chloroform for GC-MS analysis. Bis(trimethylsilyl)tri-
fluoroacetamide (Supelco) in the presence of pyridine was used to
prepare TMS derivatives. An internal standard was added after the
enzymatic reactions to determine product yields.
GC-MS analyses
The GC-MS analyses were performed with a Shimadzu GC-MS
QP2010 Ultra, using a fused-silica DB-5HT capillary column (30 m
0.25 mm internal diameter, 0.1 mm film thickness) from J&W Scien-
tific.[60] The oven was heated from 120 8C (1 min) to 300 8C (15 min)
at 5 8C·min1. The injection was performed at 300 8C, the transfer
line was kept at 300 8C, and helium was used as carrier gas.
Compounds were identified by mass fragmentography, and by
comparison of the mass spectra with those of the Wiley and NIST
libraries and standards, and quantitation was obtained from total-
ion peak area by using the response factors of the same reaction
products (25-hydroxycholecalciferol and 25-hydroxyergocalciferol).
These two standards were also used as external standards for cal-
culation of product yields. The relative abundance of the hydroxy-
lated product incorporating one 18O2 atom in the H2
18O2 reactions
described above was estimated by peak integration using the cor-
responding ion with a 2 m/z increase (with correction from interfer-
ing ions in H2
16O2 spectra, when required).
NMR analyses
The structure of the 25-hydroxy products was confirmed by 1H, 13C,
and HSQC NMR spectroscopy (the latter enabling assignment in
the 1D spectra). Spectra of both the products and the standards
were acquired. The NMR spectra were acquired on a Bruker Biospin
(Billerica, MA) AVANCE 500 MHz spectrometer fitted with a cryogen-
ically cooled 5 mm TCI gradient probe with inverse geometry
(proton coils closest to the sample).
25-Hydroxycholecalciferol : 1H NMR (500 MHz, CDCl3): d=0.55 (3H,
s, 18-H), 0.94 (1H, d, J=6.5 Hz, 21-H), 1.06 (1H, m, 22-H), 1.22 (3H,
s, 26-H), 1.22 (3H, s, 27-H), 1.23 (1H, m, 23-H), 1.27 (1H, m, 16-H),
1.28 (1H, m, 14-H), 1.29 (1H, m, 12-H), 1.37 (1H, m, 22-H), 1.38 (1H,
m, 20-H), 1.39 (1H, m, 24-H), 1.42 (1H, m, 23-H), 1.44 (1H, m, 24-H),
1.47 (2H, m, 11-H), 1.53 (1H, m, 15-H), 1.66 (1H, m, 15-H), 1.67 (1H,
m, 2-H), 1.67 (1H, m, 9-H), 1.87 (1H, m, 16-H), 1.92 (1H, m, 2-H),
1.98 (1H, m, 17-H), 2.06 (1H, m, 12-H), 2.17 (1H, m, 1-H), 2.40 (1H,
m, 1-H), 2.57 (1H, dd, J=3.7, 13.1 Hz, 4-H), 2.82 (1H, m, 9-H), 3.95
(1H, bm, 3-H), 4.82 (1H, m, 19-H), 5.05 (1H, m, 19-H), 6.03 (1H, d,
J=11.2 Hz, 7-H), 6.23 ppm (1H, d, J=11.2 Hz, 6-H); 13C NMR
(500 MHz, CDCl3): d=12.2 (C-18), 19.0 (C-21), 21.0 (C-23), 22.4 (C-
11), 23.7 (C-15), 27.8 (C-16), 29.2 (C-9), 29.4 (C-27), 29.5 (C-26), 32.1
(C-1), 35.3 (C-2), 36.3 (C-20), 36.6 (C-22), 40.7 (C-12), 44.6 (C-24),
46.0 (C-13), 46.1 (C-4), 56.5 (C-17), 56.7 (C-14), 69.4 (C-3), 71.3 (C-
25), 112.6 (C-19), 117.7 (C-7), 122.2 (C-6), 135.2 (C-5), 142.4 (C-8),
145.3 ppm (C-10).
25-Hydroxyergocalciferol : 1H NMR (500 MHz, CDCl3): d=0.56 (3H,
s, 18-H), 1.00 ppm (3H, d, J=6.9 Hz, 28-H), 1.04 (3H, d, J=6.7 Hz,
21-H), 1.13 (3H, s, 26-H), 1.17 (3H, s, 27-H), 1.26 (1H, m, 16-H), 1.31
(1H, m, 12-H), 1.34 (1H, m, 14-H), 1.46 (2H, m, 11-H), 1.54 (1H, m,
15-H), 1.68 (1H, m, 15-H), 1.68 (1H, m, 2-H), 1.68 (1H, m, 9-H), 1.71
(1H, m, 16-H), 1.92 (1H, m, 2-H), 1.96 (1H, m, 12-H), 1.99 (1H, m,
17-H), 2.07 (1H, m, 20-H), 2.11 (1H, m, 24-H), 2.18 (1H, m, 1-H),
2.29 (1H, dd, J=13.0, 7.3 Hz, 4-H), 2.40 (1H, m, 1-H), 2.57 (1H, dd,
J=13.0, 3.7 Hz, 4-H), 2.83 (1H, m, 9-H), 3.95 (1H, m, 3-H), 4.81 (1H,
m, 19-H), 5.04 (1H, m, 19-H), 5.30 (1H, dd, J=15.3, 8.2 Hz, 23-H),
5.37 (1H, dd, J=15.3, 8.3 Hz, 22-H), 6.03 (1H, d, J=11.3 Hz, 7-H),
6.23 (1H, d, J=11.3 Hz, 6-H); 13C NMR (500 MHz, CDCl3): d=12.4 (C-
18), 15.8 (C-28), 21.1 (C-21), 22.4 (C-11), 23.7 (C-15), 26.5 (C-26), 27.2
(C-27), 27.9 (C-16), 29.1 (C-9), 32.1 (C-1), 35.3 (C-2), 40.6 (C-12), 40.6
(C-20), 46.0 (C-13), 46.1 (C-4), 48.3 (C-24), 56.4 (C-14), 56.5 (C-17),
69.3 (C-3), 72.5 (C-25), 112.6 (C-19), 117.7 (C-7), 122.6 (C-6), 129.3
(C-23), 135.3 (C-5), 139.2 (C-22), 142.2 (C-8), 145.2 ppm (C-10).
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